Genentech Pays Orionis US$47 M Upfront for Molecular Glue Medicines
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 10 (Table of Contents)
Published: 7 Oct-2023
DOI: 10.3833/pdr.v2023.i10.2806 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Investing further into molecular glue degraders, Genentech has signed a multi-year collaboration with Orionis Biosciences to develop small molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS